Compare

Illumina vs Labcorp

MonkScore ranges and fundamentals, side by side

Key facts

Illumina and Labcorp: key facts

  • In fiscal 2025, Illumina, Inc. reported revenue of $4.3B and net income of $850.0M.
  • In fiscal 2025, Labcorp Holdings Inc. reported revenue of $14.0B and net income of $876.5M.
  • Illumina, Inc.'s revenue fell 1.1% a year from fiscal 2021 to fiscal 2025.
  • Labcorp Holdings Inc.'s revenue grew 1.5% a year from fiscal 2021 to fiscal 2025.
  • Illumina, Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • Labcorp Holdings Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • In the twelve months to 27 September 2026, Illumina, Inc. reported revenue of $4.5B and net income of $895.0M.
  • In the twelve months to 30 September 2026, Labcorp Holdings Inc. reported revenue of $14.6B and net income of $1.0B.

Side by side

Illumina and Labcorp, side by side

Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.

FigureIllumina, Inc.NASDAQ:ILMNLabcorp Holdings Inc.NYSE:LH
MonkScore
MonkScore range90–100as of November 202650–59as of November 2026
Sector rank32 of 637 in Healthcare301 of 637 in Healthcare
How this score is madeDisclaimer
Profile
SectorHealthcareHealthcare
IndustryMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Latest fiscal year
Revenue$4.3BFY 2025$14.0BFY 2025
Net income$850.0MFY 2025$876.5MFY 2025
Free cash flow$931.0MFY 2025$1.2BFY 2025
Operating cash flow$1.1BFY 2025$1.6BFY 2025
Total debt$2.6BFY 2025$7.2BFY 2025
Cash$1.4BFY 2025$532.3MFY 2025
Last 12 months
Revenue$4.5Bto 27 September 2026$14.6Bto 30 September 2026
Net income$895.0Mto 27 September 2026$1.0Bto 30 September 2026
Free cash flow$1.1Bto 27 September 2026$1.3Bto 30 September 2026
Operating cash flow$1.2Bto 27 September 2026$1.8Bto 30 September 2026
Total debt$2.3Bto 27 September 2026$6.8Bto 30 September 2026
Cash$1.3Bto 27 September 2026$261.8Mto 30 September 2026

MonkStreet provides research, not investment advice.